Loading
Latest filing published 14 Jun 2021 for Evofem Biosciences, Inc., €8,797.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Our data holds just one disclosure by Anthony Stephen O'Brien, dated 14 June 2021, reporting an open-market purchase worth €8,797 in Evofem Biosciences, Inc. Further filings will be added here. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
1 of 1 declaration